Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
出版年份 2014 全文链接
标题
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
作者
关键词
Interleukin-21, Sorafenib, Renal cell carcinoma (RCC), Immunotherapy, Cytokine, VEGF, Tyrosine kinase inhibitors (TKI), Durable response, Targeted therapy
出版物
Journal for ImmunoTherapy of Cancer
Volume 2, Issue 1, Pages 2
出版商
Springer Nature
发表日期
2014-01-27
DOI
10.1186/2051-1426-2-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
- (2011) Camillo Porta et al. BJU INTERNATIONAL
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
- (2011) E. Herrmann et al. WORLD JOURNAL OF UROLOGY
- A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)
- (2010) Viktor Grünwald et al. ACTA ONCOLOGICA
- Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
- (2010) Jorge A. Garcia et al. CANCER
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
- (2010) Camillo Porta et al. KIDNEY INTERNATIONAL
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
- (2009) I. D. Davis et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. Clinical Genitourinary Cancer
- Antitumor Efficacy of Recombinant Human Interleukin-2 Combined with Sorafenib Against Mouse Renal Cell Carcinoma
- (2009) M. Iguchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
- The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
- (2009) M. Krusch et al. JOURNAL OF IMMUNOLOGY
- Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2009) Daniel C. Cho et al. JOURNAL OF IMMUNOTHERAPY
- Angiostatic activity of the antitumor cytokine interleukin-21
- (2008) K. Castermans et al. BLOOD
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
- (2008) Arkadiusz Z. Dudek et al. CANCER
- IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma
- (2008) Klaus Stensgaard Frederiksen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma
- (2008) John A. Thompson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment
- (2008) Seunghee Kim-Schulze et al. MOLECULAR THERAPY
- Interleukin 21: combination strategies for cancer therapy
- (2008) Kresten Skak et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More